Clinical trials
Febrile Neutropenia clinical trials
Below are recruiting febrile neutropenia clinical trials, each written for real people, not researchers. We’re tracking 11 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05786495Recruiting
Short antibiotic treatment for high-risk fever with low white cells
This study tests whether adults with “high-risk febrile neutropenia” can safely get a shorter course of antibiotics. It may help reduce side effects from antibiotics while still keeping infections under control.
EdmontonAges 18 years+ - NCT05926063RecruitingPhase 4
Stopping antibiotics after 3 days for high-risk neutropenia
This study tests whether it is safe to stop broad antibiotics after 3 days in people at high risk of infection from low white blood cells (neutropenia) who are hospitalized with fever. It may reduce antibiotic exposure, while still watching closely to keep you safe.
Leuven, Vlaams-BrabantAges 16 years+ - NCT07277387Recruiting
Predicting complications in high-risk fever with low white blood cells
This trial studies whether proteins in your blood can predict complications when you have a fever and very low white blood cells after cancer treatment. It aims to help doctors choose the best antibiotics early on.
Barcelona, BarcelonaAges 18 years+ - NCT07187908RecruitingPhase 2
Study of Efbemalenograstim Alfa to prevent low white blood cell counts in cancer patients
This trial tests if a drug called Efbemalenograstim Alfa can help prevent a serious drop in white blood cells (febrile neutropenia) during chemotherapy. It is for patients with solid tumors who have a high or intermediate risk of this condition.
Zhengzhou, HenanAges 18–75 - NCT06293677RecruitingPhase 4
Antibiotic Dosing for Kids With Cancer and Fever
This study tests whether adjusting antibiotic doses based on how fast your kidneys clear the medicine can better treat infections in children with cancer who have a fever and low white blood cells (neutropenia). It aims to improve recovery and reduce side effects.
Lausanne, Canton of VaudAges 2 months–18 years - NCT07372131Recruiting
Shorter antibiotics for high-risk fever with low white blood cells
This study looks at how long antibiotics should be given to cancer patients with fever and very low white blood cell counts after finding a certain type of bacteria (Gram-negative) in their blood. The goal is to find the best treatment duration to help patients recover without complications.
Rozzano, MilanAges 18 years+ - NCT06342115RecruitingPhase 4
Ceftolozane/tazobactam vs meropenem for febrile neutropenia with ESBL risk
This trial tests whether a newer antibiotic (ceftolozane/tazobactam) works as well as the standard drug (meropenem) for treating fever and low white blood cell counts in people who carry or are at risk for a certain type of resistant bacteria (ESBL). If you are colonized with ESBL or have recently used certain antibiotics, you may be eligible.
São PauloAges 18 years+ - NCT07724756RecruitingPhase 2
Testing QLC2519 with chemotherapy for pediatric sarcoma
This trial tests a new drug (QLC2519) given alongside a standard chemotherapy regimen called VDC/IE for children and teens with sarcoma. The goal is to see if it can help treat their cancer more effectively.
BeijingAges birth–18 years - NCT07204522Recruiting
Antibiotic therapy for fever with low white blood cells in blood cancer
This trial tests whether an antibiotic called ceftazidime-avibactam (CAZ-AVI) can help patients with blood cancers who have a fever and very low infection-fighting white blood cells. It may be an option for people whose doctors plan to use this specific antibiotic to treat their fever.
Taiyuan, ShanxiAges 18–75 - NCT05815628Recruiting
Testing next-generation sequencing in neutropenic sepsis
This trial studies whether advanced genetic testing (next-generation sequencing) can help doctors better understand and manage neutropenic sepsis—a serious infection risk when white blood cell counts are too low. You may be considered if you develop fever or sepsis quickly (within 24 hours) while your counts are low.
CologneAges 18 years+ - NCT06616571RecruitingPhase 4
Testing a medicine to prevent low white blood cell counts from chemo
This trial tests a new way to give a medicine that helps your body make white blood cells after chemotherapy for breast cancer. It may help prevent serious infections.
Jinan, ShandongAges 18 years+
Hear when a new Febrile Neutropenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for febrile neutropenia?
- Yes. Clin2 currently lists 11 recruiting febrile neutropenia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a febrile neutropenia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a febrile neutropenia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.